Dr. Askal Ali

 

EDUCATION

• Ph.D., Pharmacoeconomics and Health Outcomes Research, Florida A&M University, 2016 
• M.A., Economics, Eastern Illinois University, Charleston Illinois, 2010 
• B.A., Economics, Bahir Dar University, Bahir Dar Ethiopia, 2005 

 

Research Interest

• Pharmacoeconomics/health economics

• Decision modeling, patient satisfaction, and self-rated health status

• Comparative effectiveness research

• Patient-centered outcomes research

• Health disparities research

• Data collection and evidence synthesis (systemic reviews and meta-analyses)

Selective Publications

• Diaby, V., Ali, A. A., & Montero, A. J. (2019). Value assessment frameworks in the United States: a call for patient engagement.

• Ali, A. A., Tawk, R., Xiao, H., Campbell, E., Semykina, A., Montero, A. J., … & Diaby, V. (2019). Comparative effectiveness of radiotherapy for early‐stage hormone receptor‐positive breast cancer in elderly women using real‐world data. Cancer medicine, 8(1), 117-127.

• Ali, A. A., Xiao, H., Tawk, R., Campbell, E., Semykina, A., Montero, A. J., & Diaby, V. (2017). Comparison of health utility weights among elderly patients receiving breast-conserving surgery plus hormonal therapy with or without radiotherapy. Current medical research and opinion, 33(2), 391-400.

• Diaby, V., Ali, A. A., Williams, K. J., Ezendu, K., Soto-Perez-de-Celis, E., Chavarri-Guerra, Y., & de Lima Lopes, G. (2017). Economic evaluation of sequencing strategies in HER2-positive metastatic breast cancer in Mexico: a contrast between public and private payer perspectives. Breast cancer research and treatment, 166(3), 951-963.

• Tan, F., Xiao, H., Gummadi, S., Koniaris, L. G., Feldman, J. D., Ali, A., … & Huang, Y. (2017). Impact of body mass index on prognosis for breast cancer patients.

• Diaby, V., Adunlin, G., Ali, A. A., Zeichner, S. B., de Lima Lopes, G., Kohn, C. G., & Montero, A. J. (2016). Cost-effectiveness analysis of 1st through 3rd line sequential targeted therapy in HER2-positive metastatic breast cancer in the United States. Breast cancer research and treatment, 160(1), 187-196.

• Diaby, V., Ali, A. A., Adunlin, G., Kohn, C. G., & Montero, A. J. (2016). Parameterization of a disease progression simulation model for sequentially treated metastatic human epidermal growth factor receptor 2 positive breast cancer patients. Current medical research and opinion, 32(6), 991-996.

• Ali, A. A., Xiao, H., Campbell, E. S., & Diaby, V. (2015). Improving health care decision making in the USA through comparative effectiveness research: the role of economic evaluation. Pharmaceutical Medicine, 29(5), 247-253.

• Diaby, V., Adunlin, G., Ali, A. A., & Tawk, R. (2014). Using quality-adjusted progression-free survival as an outcome measure to assess the benefits of cancer drugs in randomized-controlled trials: case of the BOLERO-2 trial. Breast cancer research and treatment, 146(3), 669-673.